Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Ochratoxin A induces apoptotic and necrotic renal cell death (CROSBI ID 122698)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Petrik, Jozsef ; Malić, Ana ; Barišić, Karmela ; Rumora, Lada ; Koszegi, Tamas ; Pepeljnjak, Stjepan ; Žanić-Grubišić, Tihana ; Čepelak, Ivana Ochratoxin A induces apoptotic and necrotic renal cell death // Croatica chemica acta, 78 (2005), 3; 447-463-x

Podaci o odgovornosti

Petrik, Jozsef ; Malić, Ana ; Barišić, Karmela ; Rumora, Lada ; Koszegi, Tamas ; Pepeljnjak, Stjepan ; Žanić-Grubišić, Tihana ; Čepelak, Ivana

engleski

Ochratoxin A induces apoptotic and necrotic renal cell death

MDCK, LLC-PK1 and RK 13 renal cells were exposed to the different OTA concentrations (2.5 to 25  g OTA/mL of medium) for 24 hours. 2.5  g OTA/mL significantly reduced the number of living cells to 69.4% for RK 13 cells, to 34.5% for LLC-PK1 cells and to 27.5% for MDCK cells, as compared to untreated control cells. We examined the effects of OTA on cell morphology by haematoxylin/eosin or with phalloidin-FITC/propidium iodide staining. In MDCK, LLC-PK1 and RK 13 cells treated with 2.5  g OTA/ mL we have observed 12%, 11% and 8.2% apoptotic cells, respectively. The structure of actin cytoskeleton was significantly changed in OTA-treated cells. The release of LDH into the culture medium was more abundant in MDCK and LLC-PK1 cells. OTA induced apoptotic and/or necrotic cell death in a cell type- and a concentration-dependent manner. Our results suggest that MDCK and LLC-PK1 cells are more sensitive to OTA than RK 13 cells.

ochratoxin A; apoptosis; necrosis; MDCK cells; LLC-PK1 cells; RK 13 cells

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

78 (3)

2005.

447-463-x

objavljeno

0011-1643

Povezanost rada

Farmacija

Indeksiranost